Several attempts have been made to therapeutically regulate the autophagic-promoting activity of IL6, and we were encouraged by the fact that tocilizumab, a novel monoclonal antibody injectable for rheumatoid arthritis that targets IL6, could achieve this therapeutic effect through specific blockade of the IL6 receptor. This evidence concerns the gene IL6 and rheumatoid arthritis.